Indication
- For the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above
Last updated on 3/14/2022Document Title | Year | Source |
A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy and safety of dasiglucagon in rescue treatment of hypoglycemia in subjects with Type 1 Diabetes Mellitus compared to placebo and with reference to GlucaGen. | 2020 | Zealand Pharma |
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with Type 1 Diabetes Mellitus (T1DM) compared to placebo. | 2020 | Zealand Pharma |
Phase 3, randomized, double-blind, placebo/active-controlled, parallel-arm trial to assess efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo/GlucaGen® as rescue therapy for severe hypoglycemia in children with T1DM treated with insulin. | 2020 | Zealand Pharma |